secwatch.observer — SEC 8-K summary
======================================

Issuer:     Decoy Therapeutics Inc. (DCOY)
CIK:        0001615219
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001615219-22-000147
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Salarius Pharma reports Q3 net loss $14.4M; seclidemstat trial paused on safety, FDA partial hold
--------------------------------------------------------------------------------

- Q3 2022 net loss $14.4M ($6.41/diluted share) vs $3.7M ($2.09) in Q3 2021; includes $8.9M goodwill impairment.
- Cash and equivalents $16.8M at Sep 30, 2022, down from $29.2M at Dec 31, 2021; cash runway into H2 2023.
- Seclidemstat sarcoma trial on partial clinical hold after SUSAR; enrollment paused in both company and MD Anderson studies.
- SP-3164 IND on track for H1 2023; favorable preclinical data presented at ASH abstract.
- Nine-month net loss $25.2M ($12.13/share) vs $8.7M ($5.41) in prior period; operating cash burn $12.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/0001615219-22-000147-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1615219/000161521922000147/flks-20221110.htm
  HTML page:      https://secwatch.observer/filing/0001615219-22-000147

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer